Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
11.52
+0.55 (5.01%)
At close: Oct 7, 2025, 4:00 PM EDT
11.50
-0.02 (-0.17%)
After-hours: Oct 7, 2025, 7:30 PM EDT
Ocular Therapeutix Revenue
Ocular Therapeutix had revenue of $13.46M in the quarter ending June 30, 2025, a decrease of -18.14%. This brings the company's revenue in the last twelve months to $56.66M, down -7.26% year-over-year. In the year 2024, Ocular Therapeutix had annual revenue of $63.72M with 9.03% growth.
Revenue (ttm)
$56.66M
Revenue Growth
-7.26%
P/S Ratio
34.42
Revenue / Employee
$206,803
Employees
274
Market Cap
2.00B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 63.72M | 5.28M | 9.03% |
Dec 31, 2023 | 58.44M | 6.95M | 13.49% |
Dec 31, 2022 | 51.49M | 7.97M | 18.32% |
Dec 31, 2021 | 43.52M | 26.12M | 150.08% |
Dec 31, 2020 | 17.40M | 13.18M | 311.71% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
OCUL News
- 12 hours ago - Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences - GlobeNewsWire
- 6 days ago - Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript - Seeking Alpha
- 7 days ago - Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock - GlobeNewsWire
- 7 days ago - Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint - GlobeNewsWire
- 4 weeks ago - Ocular Therapeutix, Inc. (OCUL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 4 weeks ago - Ocular Therapeutix: A High-Stakes Bet On Becoming The New Standard Of Care - Seeking Alpha
- 2 months ago - Ocular Therapeutix, Inc. (OCUL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences - GlobeNewsWire